Drug Profile
Glamepa
Alternative Names: SC 101aLatest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator Scotia Pharmaceuticals [CEASED]
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases
Most Recent Events
- 04 Jul 2000 Discontinued-I for Cancer metastases in United Kingdom (IV)
- 04 Jul 2000 Discontinued-I for Cancer metastases in United Kingdom (PO)
- 04 Sep 1997 Phase-I clinical trials for Cancer metastases in United Kingdom (IV)